A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment
Clinical trial NCT04872634 · UNKNOWN
Trial details
- NCT number
- NCT04872634
- Sponsor
- NKMAX Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-08
- Primary completion
- 2023-05-26
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.